Rituximab biosimilar - Apobiologix
Latest Information Update: 10 Feb 2017
At a glance
- Originator Apobiologix
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD200 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 10 Feb 2017 Preclinical trials in Autoimmune disorders in USA (Parenteral)
- 10 Feb 2017 Preclinical trials in Cancer in USA (Parenteral)